Twist Bioscience Corporation Operating Lease Liability
Twist Bioscience Corporation (TWST) had Operating Lease Liability of $93.59 million as of 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Balance Sheet › Liabilities
us-gaap:OperatingLeaseLiability · last filed 2026-08-03
- 2026-06-30: Operating Lease, Liability $93.59M.
- 2026-03-31: Operating Lease, Liability $95.84M.
- 2025-12-31: Operating Lease, Liability $98.05M.
- 2025-09-30: Operating Lease, Liability $75.57M.
| Period end | Operating Lease, Liability |
|---|---|
| 2026-06-30 | $93.59M 10-Q · filed 2026-08-03 |
| 2026-03-31 | $95.84M 10-Q · filed 2026-05-04 |
| 2025-12-31 | $98.05M 10-Q/A · filed 2026-02-26 |
| 2025-09-30 | $75.57M 10-K · filed 2025-11-17 |
| 2025-06-30 | $78.15M 10-Q · filed 2025-08-04 |
| 2025-03-31 | $80.30M 10-Q · filed 2025-05-05 |
| 2024-12-31 | $82.62M 10-Q · filed 2025-02-03 |
| 2024-09-30 | $85.03M 10-K · filed 2024-11-18 |
| 2024-06-30 | $87.18M 10-Q · filed 2024-08-02 |
| 2024-03-31 | $89.42M 10-Q · filed 2024-05-02 |
| 2023-12-31 | $91.88M 10-Q · filed 2024-02-02 |
| 2023-06-30 | $93.03M 10-Q · filed 2023-08-07 |
| 2023-03-31 | $91.22M 10-Q · filed 2023-05-08 |
| 2022-12-31 | $93.97M 10-Q · filed 2023-02-07 |
| 2022-06-30 | $78.60M 10-Q · filed 2022-08-08 |
| 2022-03-31 | $79.66M 10-Q · filed 2022-05-06 |
| 2021-12-31 | $72.97M 10-Q · filed 2022-02-09 |
| 2021-06-30 | $61.39M 10-Q · filed 2021-08-09 |
| 2021-03-31 | $28.76M 10-Q · filed 2021-05-07 |
| 2020-12-31 | $30.13M 10-Q · filed 2021-02-09 |
| 2020-09-30 | $31.25M 10-K · filed 2020-11-27 |
| 2020-06-30 | $32.42M 10-Q · filed 2020-08-12 |
| 2020-03-31 | $34.22M 10-Q · filed 2020-05-13 |
| 2019-12-31 | $35.91M 10-Q · filed 2020-02-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |